Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system

Trial Profile

A retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2018 Results assessing utilization and real-world effectiveness with EBR/GZR-containing regimens by treatment duration among participants with HCV GT1b (n=3440), presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 26 Apr 2017 New trial record
    • 21 Apr 2017 Results (n=2436) from this trial were presented at the The International Liver Congress 2017, according to a Merck and Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top